Skip to content
Sign in
Venture capitalBacked 1 network startup

Breakout Ventures

San Francisco early-stage investor pairing technology with science: drug discovery, climate, neurotech and lab automation (ZymoChem).

San Francisco, United States breakout.vc LinkedIn
Ticket
—Not published
Assets under management
—
Founded
—
Stages
Seedto Series A
Network startups backed
1
Co-investors
5most often with Cavallo Ventures

How they invest

Founders pairing technology with science: drug discovery, climate, neurotech and lab automation. Portfolio (Twelve, Noetik, Phantom Neuro, General Sense, Vitra Labs, ZymoChem) mixes synthetic biology, carbon tech and neurotech.

Stage and ticket

Seed and Series A; ticket not disclosed.

Geography

North America.

Thesis

Backs founders pairing technology with science (drug discovery, climate, neurotech, lab automation).

What makes them say yes

  • Science-based moat with a platform
  • Credible path to a large market (climate, therapeutics, neuro)
  • North American founders

Red flags

  • Science without platform scalability
  • No North American base

Sectors

  • Biotech & life sciences
  • Climate & energy
  • Deep tech & materials
  • HealthTech

Stages

  • Seed
  • Series A

Geographies

  • North America

How to approach

Warm intro via ZymoChem (Breakout Series A, network peer) or via Phantom Neuro for neurotech. Lead with data and platform breadth.

Portfolio

1 network startup · 5 other companies

Science-heavy platforms: carbon transformation (Twelve), AI-biology (Noetik), neurotech (Phantom Neuro), synbio materials (ZymoChem).

Gaps in the portfolio

  • No network neurotech company
  • No network lab-tools company

Network startups

  • ZymoChem2026 World Champion

    Carbon-efficient microbial fermentation platform producing BAYSE, a bio-based superabsorbent designed to replace petroleum SAP in hygiene products.

    United States · Biotech & life sciences

    • Series A · $21M · 16 Jan 2024LeadSource

Other portfolio companies

From the investor's own sources. These companies are not on the network yet.

  • General Sense
  • Noetik
  • Phantom Neuro
  • Twelve
  • Vitra Labs

Network startups that fit

5 analysed

San Diego maker of fully defined, serum-free stem cell media that lower cost and variability for iPSC research and biomanufacturing.

US serum-free stem-cell culture media sold to UC San Diego, Tufts and Penn State: lab-tools science with revenue at pre-seed.

55%confidence

Evidence from the records

  • “Backs founders pairing technology with science (drug discovery, climate, neurotech, lab automation).”
  • “Serum-free culture media for stem cells”
  • “Range of 11 media and reagents on sale”
Intro path
ZymoChem (Breakout portfolio)
First step
Pitch the media platform as cell-therapy infrastructure.

Davis biotech using baker’s yeast to deliver RNAi that kills insect pests, starting with cockroaches, without hazardous chemicals.

US yeast-based RNAi biopesticides: synbio for agriculture, adjacent to ZymoChem. R&D stage at seed.

45%confidence

Evidence from the records

  • “Yeast-based RNAi biopesticides”
  • “United States”
Intro path
ZymoChem (synbio peer)
First step
Ask ZymoChem for an intro.

Lab-stage electrochemical route to ammonia at room temperature from air and water, targeting distributed, low-carbon nitrogen fertiliser.

US green ammonia, lab technology published in ACS Energy Letters: climate chemistry like Twelve. Pre-pilot.

40%confidence

Evidence from the records

  • “Green ammonia / fertilizer decarbonization”
  • “ACS Energy Letters”
First step
Share pilot plan and techno-economics.

EPFL spin-off making soft, stretchable cortical electrodes for minimally invasive brain interfaces, with first-in-human epilepsy data and a $7.5M seed.

Soft brain-computer interface electrodes with first-in-human data: neurotech fit, but Swiss and US$13.8M raised.

30%confidence

Evidence from the records

  • “Neurotechnology / brain-computer interfaces”
  • “first-in-human evaluation”
Intro path
Connecticut Innovations (Neurosoft investor, US)
First step
Pitch Breakout if US operations expand.

Preclinical biotech licensing University of Miami RNA aptamers to regenerate beta cells in type 1 diabetes and target solid tumours.

US RNA aptamers for type 1 diabetes and tumours at pre-seed: drug discovery, but very early.

25%confidence

Evidence from the records

  • “RNA aptamers – type 1 diabetes and solid tumors”
  • “Pre-seed”
First step
Return with in vivo data.

Analyst reading of 21 Nov 2026, from the public record of the network. Method: analyst-ai.

Co-investors

Most often with Cavallo Ventures, GS Futures, and KdT Ventures

Sources

  1. 1breakout.vc/

Profile compiled from public sources. Unknown fields are left empty rather than estimated.